An observational study in Spinocerebellar Ataxia (SCA), sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by BioSensics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Spinocerebellar Ataxias with a site in United States — 7 open to participants now, 14 under way, 2 of them phase 3. Spinocerebellar Ataxias · United States.
Among the 36 studies in Spinocerebellar Ataxias with a site in United States, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2026, is one of 14 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 35th registered.
95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.
Browse Spinocerebellar Ataxias studies →7 of the 36 studies in Spinocerebellar Ataxias with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 21–89
University of California, San Francisco · Sites in United States
Ages 21–89
Sanford Health · Sites in United States
Lauren Moore · Sites in United States, Canada
Ages 6+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4
First in 2008; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 128 across 25 observational studies indexed under Spinocerebellar Ataxias.
Median enrollment 20 across the 22 interventional studies, 164 across the 14 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
BioSensics is the lead sponsor of 12 studies on the registry; 8 are open to participants now.
BioSensics has 1 study filed under Spinocerebellar Ataxias — fewer than ten, so there is no comparison to draw.
3 of the studies in Spinocerebellar Ataxias with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529252Mayo ClinicInvestigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases | 2026-12 |
| NCT07930481University of WashingtonNon-invasive Spinal Stimulation for Gait in Genetic Spasticity | 2027-06 |
| NCT02994719Beth Israel Deaconess Medical CenterGait Analysis in Neurological Disease | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Spinocerebellar Ataxias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study. Subjects with a documented diagnosis of spinocerebellar ataxia (SCA) will be screened and recruited to participate at two clinical sites: Johns Hopkins University (JHU) and Columbia University (CU).
Researchers at BioSensics, JHU, and CU will use wearable sensors computerized speech, psychomotor, and ocular assessments to evaluate the feasibility of using digital health technologies to monitor symptoms in SCA. Researchers will also measure the Scale for the Assessment and Rating of Ataxia (SARA) and other SCA clinical assessments.
The solution will be deployed for 25 participants with SCA for approximately 12 months with 5 study visits (Screening/Baseline, Day 1, Day 30, Day 90, Day 180, Day 360).
The spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of rare, autosomal dominant neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connecting pathways. The four most common subtypes (SCA1, SCA2, SCA3, and SCA6) are caused by expanded polyglutamine-coding CAG repeats, and collectively account for the majority of dominantly inherited ataxias worldwide. The cardinal feature across subtypes is progressive ataxia affecting gait, stance, limb coordination, and speech, frequently accompanied by oculomotor abnormalities and, in some subtypes, extracerebellar signs such as spasticity, peripheral neuropathy, and parkinsonism. Symptoms typically begin in adulthood and progress over many years, leading to severe disability and reduced life expectancy.
The principal means of measuring ataxia severity is the Scale for the Assessment and Rating of Ataxia (SARA), which is the most widely applied clinical outcome assessment (COA) for genetic ataxias and has been used as the primary endpoint in large natural history cohorts and randomized controlled trials. Although the SARA has demonstrated good inter-rater reliability and has been validated across multiple SCA subtypes, it is inherently subjective and semi-quantitative, requires trained personnel to administer, and may not be sufficiently sensitive to detect incremental but clinically meaningful changes over short follow-up intervals.
Movement-associated symptoms are a core feature of SCA and have a substantial negative impact on quality of life. Impairments in gait and balance contribute to falls and loss of independence, while dysarthria and impaired limb coordination affect communication and activities of daily living. Because these assessments are conducted infrequently, typically in a clinic setting, they may not accurately represent an individual's true functional status during everyday life. However, the increasing understanding of disease pathomechanisms and the development of gene-targeting and other novel therapeutic approaches have raised expectations for disease-modifying treatments. The key challenge in developing new therapeutics for SCA and other neurological disorders is that current disease assessment is largely subjective and requires in-person, in-clinic evaluation.
Digital measures, such as those proposed in this study, can provide objective, sensitive, and real-world assessments of how individuals are functioning. A growing body of evidence demonstrates that digital biomarkers derived from body-worn inertial sensors can quantify ataxia-specific gait and balance impairments, and correlate strongly with clinician-rated SARA scores.
Beyond gait and balance, multi-modal digital assessment of speech, hand function, and oculomotor control may capture complementary domains of cerebellar dysfunction that are affected in SCA. Acoustic analysis of speech can quantify dysarthria, finger tapping can characterize upper-limb bradykinesia and dysrhythmia, and oculomotor testing can capture saccadic and antisaccadic abnormalities that are characteristic of cerebellar disease.
Thus, a system that can objectively, sensitively, and frequently monitor multiple clinical domains (motor, speech, and oculomotor function) is necessary to understand the pattern of evolving impairment in individuals with SCA and to support the identification of endpoint measures for therapeutic trials. This study will evaluate the feasibility of a multi-modal digital monitoring platform in a cohort of individuals with SCA and will characterize the relationship between digital measures and established clinical and patient reported outcomes.
Adults with SCA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physical Activity Monitoring - Daily Number of Steps (count)
Following each clinical visit, participants will be asked to wear a PAMSys pendant sensor, PAMSys ULM wrist sensors, and PAMSys Gait for 7 days at home. The average daily number of steps will be measured using the PAMSys pendant.
Time frame: 12 months
Physical Activity Monitoring - Total number of goal-directed movement (GDM)
Following each clinical visit, participants will be asked to wear a PAMSys ULM sensor, a wearable sensor for long-term monitoring of upper limb and activities of daily living (ADL). The sensor will record the daily number GDMs as participants perform ADLs.
Time frame: 12 months
Physical Activity Monitoring - Stride Velocity (m/s)
Following each clinical visit, participants will be asked to wear a PAMSys Gait sensor, a wearable sensor for long-term monitoring of gait during activities of daily living (ADL). The sensor will record the average stride velocity (m/s) during ADLs.
Time frame: 12 months
Scale for the Assessment and Rating of Ataxia (SARA)
The SARA is an 8-item clinical sale to measure severity and progression of cerebellar ataxia. Total scores range from 0 (no ataxia) to 40 (most severe ataxia).
Time frame: 12 months
Digital Speech Assessment - Intelligibility (%)
Using a study tablet, participants will read the Rainbow Passage. Intelligibility is a digital measure of speech clarity that determines how easily a listener can understand spoken words. Intelligibility ranges scores from 0 to 100%
Time frame: 12 months
1 Minute Walk Test - Gait Speed (m/s)
Performed at each clinical visit, the participant will complete the 1 Minute Walk Test. Gait speed will be measured using LEGSys.
Time frame: 12 months
Digital Occulomotor Assessments - Median velocity (pixel/s)
Using a study tablet, participants will perform a series of oculomotor assessments (saccades). The video will be analyzed to calculate the median velocity of the pupil during saccade movements.
Time frame: 12 months
EuroQoL 5-Dimension 5-Level questionnaire (EQ-5D-5L)
The EQ-5D-5L is a standardized 5-item tool used to measure health-related quality of life. EQ-5D-5L scores are interpreted by analyzing three distinct components: a 5-digit health profiles. Each dimension uses five severity levels (1 = no problems, 2 = slight, 3 = moderate, 4 = severe, 5 = extreme/unable to).
Time frame: 12 months
1 Minute Walk Test with Cognitive Load- Gait Speed (m/s)
Performed at each clinical visit, the participant will complete the 1 Minute Walk Test with cognitive load (counting backwards). Gait speed will be measured using LEGSys.
Time frame: 12 months
Timed Up and Go (TUG) - Sit to Stand duration (s)
Performed at each clinical visit, the participant will complete the TUG Test. Sit to stand duration will be measured using LEGSys.
Time frame: 12 months
30S Chair Sit to Stand - Sit to Stand duration (s)
Performed at each clinical visit, the participant will complete the 30S Chair Sit to Stand Test. Sit to stand duration will be measured using LEGSys.
Time frame: 12 months
Digital Occulomotor Assessment - Median duration (s)
Using a study tablet, participants will perform a series of oculomotor assessments (saccades). The video will be analyzed to calculate the median duration of the pupil during saccade movements.
Time frame: 12 months
EQ-VAS (Visual Analog Scale)
The EQ VAS: The participant self-rates their overall health on a vertical thermometer-like scale from 0 to 100, where 100 is the best health the participant can imagine, and 0 is the worst health the participant can imagine.
Time frame: 12 months
Digital Fine Motor Control Assessment - Number of taps (count)
Using a study tablet, participants will perform a series of tapping tests. The tablet will calculate the count of all recorded taps made by a finger on the screen.
Time frame: 12 months
Digital Fine Motor Control Assessment - Average tap rate (s)
Using a study tablet, participants will perform a series of tapping tests. The tablet will calculate the number of taps per second.
Time frame: 12 months
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.